Entacapone
Entacapone is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Entacapone; Generic name: ENTACAPONE; Drug class: Catechol-O-Methyltransferase Inhibitor [EPC].
| Brand name | Entacapone |
|---|---|
| Generic name | ENTACAPONE |
| Drug class | Catechol-O-Methyltransferase Inhibitor [EPC] |
| Manufacturer | Lannett Company, Inc. |
| Used for | INDICATIONS AND USAGE Entacapone tablets USP are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease (see CLINICAL PHARMACOLOGY, Clinical Studies ). Entacapone's effectiveness has not been systematically evaluated in patients with Parkinson's disease who do not experience end-of-dose "wearing-off". |
| Dosage | DOSAGE AND ADMINISTRATION The recommended dose of entacapone is one 200 mg tablet administered concomitantly with each levodopa and carbidopa dose to a maximum of 8 times daily (200 mg × 8 = 1,600 mg per day). Clinical experience with daily doses above 1,600 mg is limited. Entacapone should always be administered in association with levodopa and carbidopa. Entacapone has no antiparkinsonian effect of its own. In clinical studies, the majority of patients required a decrease in daily levodopa dos |
| Warnings | WARNINGS Monoamine oxidase (MAO) and COMT are the two major enzyme systems involved in the metabolism of catecholamines. It is theoretically possible, therefore, that the combination of entacapone and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. For this reason, patients should ordinarily not be treated concomitantly with entacapone and a non-selective MAO inhibitor |
| Active ingredient(s) | ENTACAPONE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bf133e4-1c17-4358-9a43-144e6bf2564f |